SCHEMBL17522792

SCHEMBL17522792

CC(=O)c1ccc(OCCCc2c(C)n[nH]c2C)c(F)c1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 5/20 0.69
▸ ALB P02768 1/20 0.69
▸ SMN1; SMN2 Q16637 7/20 0.51
▸ HSD17B10 Q99714 6/20 0.51
▸ MAPT P10636 4/20 0.51
▸ GAA P10253 1/20 0.51
▸ LMNA P02545 4/20 0.48
▸ HTT P42858 3/20 0.48
▸ TSHR P16473 1/20 0.48
▸ RECQL P46063 1/20 0.48
▸ MEN1 O00255 4/20 0.48
▸ KMT2A Q03164 4/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ MAPK1 P28482 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17525272 0.91 TTR (0.83) TTRALBSMN1; SMN2HSD17B10MAPT
SCHEMBL24953188 0.91 TTR (0.83) TTRALBSMN1; SMN2HSD17B10MAPT
SCHEMBL19795012 0.89 TTR (0.66) TTRALBSMN1; SMN2HSD17B10MAPT
SCHEMBL19801746 0.89 TTR (0.84) TTRALBSMN1; SMN2HSD17B10MAPT
SCHEMBL17522783 0.87 TTR (0.81) TTRALBSMN1; SMN2HSD17B10MAPT
SCHEMBL17522788 0.84 TTR (0.62) TTRALBSMN1; SMN2HSD17B10MAPT
Acoramidis SCHEMBL15816954 0.81 TTR (1.00) TTRALBSMN1; SMN2HSD17B10MAPT
Acoramidis SCHEMBL29350324 0.81 TTR (1.00) TTRALBSMN1; SMN2HSD17B10MAPT
Acoramidis SCHEMBL20475239 0.81 TTR (0.98) TTRALBSMN1; SMN2HSD17B10MAPT
Acoramidis SCHEMBL29390976 0.81 TTR (0.98) TTRALBSMN1; SMN2HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180021446-A1 SYSTEMS FOR STABILIZING AND DELIVERING ACTIVE AGENTS MAHA THERAPEUTICS, INC. 2018-01-25 — — US disclosed
US-20160045609-A1 CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE MAHA THERAPEUTICS, INC. 2016-02-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180021446-A1 SYSTEMS FOR STABILIZING AND DELIVERING ACTIVE AGENTS SERPINA6, SERPINC1, SERPINE1 TTR 67/4885ALB 30/4885SMN1; SMN2 262/4885
US-20160045609-A1 CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE TTR, TTPA, SERPINA6 TTR 1/4885ALB 4/4885SMN1; SMN2 1239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback